Navigation Links
Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
Date:5/8/2012

ring additional options to people who suffer from the challenging and diverse symptoms of depression."

"These study results contribute to the growing understanding of the compound," said Stephen Brannan, M.D., Development Therapeutic Area Head, CNS, at Takeda. "Lundbeck and Takeda are committed to further investigating Lu AA21004 to better understand its mechanism of action in depression."

The study was a multi-national, randomized, double-blind, placebo-controlled, active-reference, fixed-dose study in elderly patients (n=452) with recurrent MDD, assessing the efficacy and tolerability of Lu AA21004 5 mg/day.  The primary endpoint was mean change from baseline in the 24-item Hamilton Depression Rating Scale (HAM-D24) total score, a measure of the severity of MDD.  These patients, aged 65 years or older, with a current major depressive episode (MDE) of at least 4-week duration, at least one previous MDE before the age of 60 years, a MADRS total score of 26 or more and a Mini Mental State Examination score of <24, were randomly assigned (1:1:1) to Lu AA21004 5 mg/day, duloxetine 60mg/day (active reference), or placebo for 8 weeks.

Withdrawal rates due to adverse events were 5.8% (Lu AA21004) and 2.8% (placebo). Nausea was reported with a significantly higher incidence for Lu AA21004 (21.8%) than for placebo (8.3%).

About Lu AA21004

Lu AA21004 is under investigation as a multimodal anti-depressant that is thought to work through a combination of two complementary mechanisms of actions: receptor activity modulation and reuptake inhibition.

In vitro studies indicate that LuAA21004 is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the SERT. In vivo non-clinical studies have demonstrated that LuAA21004 modulates neuronal firing and neurotransmitter release in multiple systems, resulting in enhanced levels of serotonin, noradrenaline, dopamine,
'/>"/>

SOURCE H. Lundbeck A/S; Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 21, 2015 ... has announced the addition of the "Craniomaxillofacial ... Growth, Trends and Forecast 2014 - 2022" ... on the craniomaxillofacial implants market studies the current ... implants are rapidly gaining popularity in the global ...
(Date:7/28/2015)... CITY , July 28, 2015  PD-Rx ... today announced that it has partnered with Dobson ... Infrastructure as a Service (IaaS) product. ... medical practices across the United States.  Using Dobson ... disaster recovery and business continuity, ensure regulatory compliance, ...
(Date:7/28/2015)... According to the new Market ... Treatment Devices, and Dermatology Diagnostic Devices [Imaging Techniques (OCT, ... - Analysis and Forecast to 2019", The global dermatology ... 2019, at a CAGR of 10.4% from 2014 to ... Dermatology Devices Market for an in-depth analysis of the ...
Breaking Medicine Technology:Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2PD-Rx Partners With Dobson Technologies 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3
... Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) ... publication of an interview of its President Deborah Jenkins ... interviews with CEOs and CFOs of publicly traded growth ... by Lynn Fosse, Senior Editor, CEOCFOInterviews.com include why Ms. ...
... Conn., May 19, 2011 Boehringer Ingelheim Pharmaceuticals, ... (dabigatran etexilate mesylate) capsules has received preferred Tier ... D plans through its pharmacy benefits manager, Prescription ... AARP Medicare Rx and AARP MedicareComplete from Secure ...
Cached Medicine Technology:WNDM President Interviewed; Discusses 2011 Outlook and Beyond 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6
(Date:7/29/2015)... ... July 29, 2015 , ... Elizabeth ... in Sarasota to be chosen by the manufacturer to offer and perform ... injectable, non-invasive way to treat and eliminate double chin fat,” Dr. Callahan explained. ...
(Date:7/29/2015)... ... July 29, 2015 , ... One may not expect to ... nursing facility, but that’s exactly what was happening on the campus of Piedmont ... 3- and 4-year-olds from Kids Only , a five-star childcare center which operates ...
(Date:7/28/2015)... ... July 29, 2015 , ... Meet a Millionaire, the premier ... evolved into a world class millionaires club, according to the site’s founders. Unlike ... attractive people seeking real, meaningful and mutually beneficial relationships and provide a first ...
(Date:7/28/2015)... , ... July 29, 2015 , ... City Sports, a ... today announced veteran retail executive Marty Hanaka as CEO. , Hanaka, who has served ... year as an operating partner at the Highland Consumer Fund has had previous tenures ...
(Date:7/28/2015)... ... July 28, 2015 , ... Jordan Valley Medical Center and ... Guidelines®-Stroke Gold Plus Award for implementing specific quality improvement measures outline by the ... Get With The Guidelines-Stroke program recognizes hospitals that demonstrate at least 85 percent ...
Breaking Medicine News(10 mins):Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 2Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 3Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 4Health News:Meet a Millionaire Announces It’s Not a Sugar Daddy Site, It’s a True Millionaires Club 2Health News:City Sports Names Marty Hanaka CEO 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3
... mosquito, a step that might one day help block the ... around the world. ,When they fed on ... than nonresistant ones, meaning they could eventually replace the ones ... Tuesday's issue of Proceedings of the National Academy of Sciences. ...
... lack of education and prevention efforts are fueling the spread ... ,According to the Times, there are 69-recorded cases ... the actual number of cases is much higher. The World ... HIV-positive. ,Nilufar Egamberdi, a World Bank consultant ...
... diseases that could result in cardio-vascular diseases, it is ... form even a deadlier combination. , ,At ... in Lucknow, capital of the north Indian state of ... generate a condition called metabolic syndrome (MS). ...
... This ‘celebration’ acquires specific significance in India,// which has ... people are reported to suffer a head injury in ... common cause of death, in the country. ,Panning ... suffers a brain injury as a result of severe injury to ...
... out strongly against the use of sunbeds or tanning beds, ... to the Working Group on artificial UV light and skin ... persons who use these tanning beds in order to avoid ... higher risks of developing melanoma, the most dreaded skin cancer. ...
... that can aptly be described as a state of content, aided by the ... ... conscious pursuit to quench his yen for happiness. For most ... Holy Grail. Different cultures take a different view of happiness. The eastern culture ...
Cached Medicine News:Health News:Malaria-resistant Mosquito Developed 2Health News:Stigma, Lack of Education, Prevent the Spread of HIV in Afghanistan 2Health News:Head Injury Awareness Day 2Health News:Head Injury Awareness Day 3Health News:The Science of Happiness 2Health News:The Science of Happiness 3Health News:The Science of Happiness 4
UST-675-P is our end-fire prostate transducer. Multiple frequencies provide extraordinary imaging capabilities for your diverse patient population, and the biopsy guide enables accurate and fast pros...
Super High Density 360 degree radial rectal transducer. High resolution in the near field and lower frequencies for deeper penetration make this transducer the optimal choice when scanning the anal c...
Our most versatile transducer for superficial imaging. Wide Band, Super High Density, multi-frequency transducer with superb Doppler and color flow sensitivity make this an excellent choice for breas...
... is our high frequency transducer which ... imaging. Multiple frequencies and superb Doppler ... our exclusive transducer technologies including Hemispheric ... excellent resolution and detail. This an ...
Medicine Products: